# The DEA Rescheduling Hearing Is Over. States Should Lead Cannabis Research > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/state-led-cannabis-research-infrastructure-next-phase/ > **Published:** 2026-07-31T17:17:11-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:05-04:00 > **Clinical Summary:** The DEA rescheduling hearing highlights the need for state-led cannabis research infrastructure to realize clinical benefits from federal rescheduling. --- CED Clinical Relevance #82 High Practice and Policy Relevance for Clinicians The DEA’s marijuana rescheduling hearing wrapped up in mid-July 2026 with post-hearing briefs due August 17, and a July 28 commentary in Clinical Therapeutics landed right into that gap between the hearing closing and a recommendation being written. The commentary argues that rescheduling’s real clinical payoff, more research access, will only materialize if states with mature medical programs build the infrastructure to use it. That is a direct, practical question for any clinic already navigating cannabis conversations with patients. Clinical Insight | CED Clinic This commentary is useful less for new data than for naming what happens in the gap between a regulatory hearing ending and a policy outcome starting. The DEA hearing on moving marijuana from Schedule I to Schedule III concluded in mid-July 2026, with a chief administrative law judge now reviewing post-hearing briefs before writing a recommendation that the DEA Administrator can accept, reject, or modify on an unspecified timeline. The commentary argues that rescheduling’s clinical promise, meaning fewer barriers to running rigorous [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), will not be realized automatically. States with established [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs and existing healthcare and scientific infrastructure are, in the authors’ view, the ones positioned to convert lowered federal barriers into real-world evidence clinicians can actually use. PolicyReschedulingResearch AccessClinical PracticeFederal Law Audience Physicians, nurse practitioners, and other clinicians who recommend or discuss [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) with patients, plus practice administrators and researchers tracking how federal rescheduling will change access to [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) and prescribing. Primary Topic A July 28, 2026 commentary in Clinical Therapeutics, published as the DEA’s marijuana rescheduling hearing concluded, arguing that states with mature medical cannabis programs should lead the next phase of [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) now that federal rescheduling has begun lowering research barriers. Source [Read the full PubMed record](https://pubmed.ncbi.nlm.nih.gov/42521587/) Table of Contents - [The DEA Rescheduling Hearing Is Over. A New Commentary Argues States Should Lead the Next Phase of Cannabis Research](#The_DEA_Rescheduling_Hearing_Is_Over_A_New_Commentary_Argues_States_Should_Lead_the_Next_Phase_of_Cannabis_Research) - [How to Read a Policy Commentary Timed to a Hearing Close](#How_to_Read_a_Policy_Commentary_Timed_to_a_Hearing_Close)[Four questions worth asking before treating this as settled news](#Four_questions_worth_asking_before_treating_this_as_settled_news) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[Nothing Changes at Your Next Appointment Yet](#Nothing_Changes_at_Your_Next_Appointment_Yet) - [The Evidence Gap Will Not Close Automatically](#The_Evidence_Gap_Will_Not_Close_Automatically) - [Lower Barriers Are Necessary but Not Sufficient](#Lower_Barriers_Are_Necessary_but_Not_Sufficient) - [The Hearing Closing Starts a Paper Process, Not a Verdict](#The_Hearing_Closing_Starts_a_Paper_Process_Not_a_Verdict) - [Litigation Is Still Running Alongside the Hearing Process](#Litigation_Is_Still_Running_Alongside_the_Hearing_Process) - [A Commentary Timed to News Is Still an Opinion Piece](#A_Commentary_Timed_to_News_Is_Still_an_Opinion_Piece) - [Downstream Effects Are Already Uneven Across Agencies](#Downstream_Effects_Are_Already_Uneven_Across_Agencies) - [Watch the Briefs, the Recommendation, and State Funding Decisions](#Watch_the_Briefs_the_Recommendation_and_State_Funding_Decisions) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## The DEA Rescheduling Hearing Is Over. A New Commentary Argues States Should Lead the Next Phase of Cannabis Research The DEA’s hearing on moving marijuana from Schedule I to Schedule III wrapped up in mid-July 2026, and the presiding judge has given participants until August 17 to file post-hearing briefs before he writes a recommendation. Days after that hearing closed, a commentary in Clinical Therapeutics argued that the clinical payoff of rescheduling depends on what states do next, not on the reclassification itself. What This Study Teaches Us This piece teaches that rescheduling is a process with real, unfinished steps, not a single finished event, and that the commentary’s central claim is about infrastructure: federal rescheduling lowers barriers to cannabis research, but converting that lowered barrier into usable clinical evidence requires states to build dedicated, independent research capacity rather than assuming better data will simply appear. Why This Matters Clinicians who discuss cannabis with patients are already operating with a thin evidence base for many indications. Whether that evidence base improves in the next several years depends heavily on decisions states make now about research infrastructure, not just on what the DEA ultimately decides about scheduling. Understanding where the hearing process actually stands, and what the commentary is and is not claiming, helps separate real developments from noise in a fast-moving policy story. Study Snapshot Content Type Peer-reviewed commentary paired with verified regulatory and news reporting (not a clinical trial) Journal Clinical Therapeutics Authors Julie K. Johnson, Drudys Ledbetter, Steph Sherer Published July 28, 2026 PMID 42521587 DOI 10.1016/j.clinthera.2026.06.023 Hearing Status DEA rescheduling hearing began June 29, 2026 and wrapped up July 15 to 16, 2026 in Arlington, Virginia Post-Hearing Briefs Due August 17, 2026, per DEA Chief Administrative Law Judge Derek Julius Interim Reclassification State-licensed medical cannabis and FDA-approved cannabis products were already moved from Schedule I to Schedule III by an April 2026 order from the Acting Attorney General, ahead of this broader hearing Major Limitation This is a three-author commentary, not an empirical study, and the DEA has not set a timeline for a recommendation or final decision Clinical Bottom Line The DEA’s rescheduling hearing has closed, but the process is not finished, and a new commentary argues that the clinical benefit of rescheduling will depend on whether states with mature medical cannabis programs build real research infrastructure rather than waiting for federal rescheduling alone to fix the evidence gap. What Actually Happened at the Hearing The DEA hearing on whether to move marijuana more broadly from Schedule I to Schedule III began June 29, 2026, at the DEA Hearing Facility in Arlington, Virginia, and wrapped up July 15 to 16 following testimony from a handful of states opposing the change. DEA Chief Administrative Law Judge Derek Julius closed the in-person proceedings without time allotted for closing arguments, so he set August 17, 2026 as the deadline for participants to file post-hearing briefs of up to 50 pages. He will use those briefs to write his own recommendation, but the final scheduling decision rests with the DEA Administrator on a timeline that has not been announced. Why Only Rescheduling Opponents Sat at the Table The DEA Administrator designated only parties opposed to rescheduling as official hearing participants, including Smart Approaches to Marijuana, the National Drug & Alcohol Screening Association, the Tennessee Bureau of Investigation, DUID Victim Voices, and the states of Nebraska, Idaho, Indiana, and Louisiana, on the grounds that supporters did not meet the legal definition of parties adversely affected by the proposed rule. DEA and FDA officials defending the proposal still presented testimony highlighting marijuana’s medical benefits and its relative safety compared with alcohol and opioids, including from an FDA scientist and a New Hampshire physician, but reform advocacy groups were not seated as designated participants and criticized the hearing for not being livestreamed. The Reclassification Already in Effect It is easy to conflate this hearing with rescheduling itself, but part of the reclassification already happened. In April 2026, the Acting Attorney General issued an order immediately moving state-licensed medical cannabis and FDA-approved cannabis products from Schedule I to Schedule III of the Controlled Substances Act. The hearing that just concluded concerns a separate, broader rule that would move marijuana more comprehensively to Schedule III. That distinction matters clinically, because the interim reclassification is already producing downstream effects while the broader rule remains undecided. What the New Commentary Actually Argues Writing in Clinical Therapeutics on July 28, 2026, Johnson, Ledbetter, and Sherer argue that federal rescheduling lowers barriers to cannabis research but does not, by itself, generate the evidence clinicians need. They contend that states with mature medical cannabis markets and existing scientific and healthcare infrastructure are best positioned to lead the next phase of [medical cannabis science](https://cedclinic.com/the-dietary-flavonoid-luteolin-negatively-affects-neuronal-differentiation/). Their specific proposal is state-authorized but independent research centers, supported by enabling legislation, sustained funding, and cross-sector partnerships, tasked with centralizing data infrastructure, standardizing metrics and documentation, and embedding equity-focused cannabis research into routine healthcare rather than treating it as a separate track. The Downstream Effects Already Showing Up The April interim reclassification is already reshaping federal paperwork and guidance in ways that touch clinical practice. The ATF has drafted an updated gun-purchase form that no longer flags medical marijuana use for recreational-only prohibition language, and the Treasury Department and IRS have said new tax guidance is coming for state-licensed cannabis businesses, which stand to gain federal deductions currently barred under IRC Section 280E. Other agencies have held the line. The Department of Transportation has said state-legal medical cannabis is still no excuse for a positive drug test among truckers, pilots, and other safety-sensitive workers, and the Department of War issued a memo confirming marijuana use remains prohibited for service members and civilian employees, even under the interim rescheduling. What Remains Genuinely Unresolved The hearing wrapping up is not the same as a decision being made. Judge Julius did not lay out an expected timeline for his recommendation or for the Administrator’s eventual action, and the broader rescheduling proposal is being challenged by several consolidated lawsuits from state attorneys general, rescheduling opponents, and at least one cannabis-focused biopharmaceutical company. A congressional committee has also voted to block federal officials from taking further steps on rescheduling, though bipartisan lawmakers have told reporters they do not expect that provision to become law. None of this changes what the commentary is arguing, but it is the honest backdrop against which its call for state-led research infrastructure should be read. How Strong Is This Evidence? The clinical claims in this article rest on two different kinds of sources that should not be blended. The commentary itself, published July 28, 2026 in Clinical Therapeutics, is a peer-reviewed but non-empirical piece, three authors offering a policy argument, not a clinical trial or systematic review. The hearing timeline, designated participants, post-hearing brief deadline, and downstream agency actions described here are drawn from DEA regulatory postings and established cannabis policy reporting, and are treated as factual background rather than as evidence for or against cannabis’s therapeutic effects. Where This Paper Deserves Skepticism A skeptical reader should note that this is a three-author commentary reflecting the authors’ policy position, not a neutral tally of the evidence or a binding legal analysis, and that its call for state-led research centers is a proposal, not something already funded or built anywhere. The hearing itself invited only rescheduling opponents as designated participants, which shaped what testimony was formally entered into the record, and the DEA has given no timeline for a recommendation or final decision. Readers should also note the litigation still pending against the rescheduling move, which means none of this is final. What This Paper Does Not Show This commentary does not show that marijuana has been rescheduled more broadly beyond the April interim reclassification, and it does not report new clinical trial data on cannabis efficacy or safety. It does not establish that any state has yet built the independent research centers it proposes, and it does not predict when or how the DEA Administrator will rule on the hearing record. How This Fits With the Broader Clinical Conversation This commentary lands at a specific, narrow moment: a formal hearing has closed, briefs are being prepared, and a recommendation has not yet been written, let alone acted on by the DEA Administrator. That is a meaningfully different moment than either the original April 2026 interim reclassification or a hypothetical future point where the broader rule is finalized. The proposal for state-led, independent research infrastructure is not new to cannabis policy discussions, but it carries more weight now that federal rescheduling has already started changing what research is permissible. Whether states act on that opening, and whether independent research centers get built with real funding rather than remaining a proposal, will likely matter more to the evidence clinicians can rely on than the scheduling outcome alone. Dr. Caplan’s Take *What strikes me most about this moment is how easy it is to mistake a hearing ending for a decision being made. The hearing closing in mid-July is a procedural milestone, not a resolution, and the commentary’s authors are right to focus attention on what happens next rather than treating rescheduling itself as the finish line.* *I agree with the paper’s central argument, but I would go further: research infrastructure without a clear plan for equitable patient access does not close the evidence gap that matters most in my exam room. States that want to lead this next phase need to fund real, independent research centers, not just announce intentions, and they need to build access alongside the science so that patients benefit from what gets learned.* What a Careful Reader Should Take Away A careful reader should take away a narrow but accurate picture: the DEA rescheduling hearing has concluded procedurally, post-hearing briefs are due August 17, 2026, and a new commentary argues that converting rescheduling into better clinical evidence will require states to build dedicated, independent cannabis research infrastructure, which has not yet happened and is not guaranteed to happen just because the hearing closed. Evidence Interpretation Guide ## How to Read a Policy Commentary Timed to a Hearing Close A commentary published just after a major regulatory hearing closes can be easy to over-read as a verdict on that hearing. It is not one. These questions help place this piece where it actually belongs in the rescheduling story. ### Four questions worth asking before treating this as settled news **Does the hearing closing mean marijuana has been rescheduled?**No. The hearing concluded procedurally in mid-July 2026, but the presiding judge has not yet written a recommendation, and the DEA Administrator has not set a timeline for a final decision on the broader rule. **Is the commentary reporting new clinical trial data?**No. It is a peer-reviewed policy commentary arguing that states should build independent research infrastructure to capture the benefit of lowered federal research barriers, not a study of cannabis efficacy or safety. **Has any state already built what the commentary proposes?**Not according to this commentary or the sources reviewed here. The state-authorized, independent research center model is presented as a proposal for what should happen next, not a description of infrastructure that already exists. **What is the safest way to describe this to a patient?**That part of medical cannabis was already reclassified to Schedule III in April 2026, that a separate, broader hearing on marijuana scheduling has closed but is not decided, and that better research access is expected but not yet guaranteed to translate into new evidence soon. The Question This Commentary Raises Now that a major hearing on rescheduling has closed, will lowered federal research barriers actually translate into better clinical evidence, or does that depend on choices states have not yet made? The Patient Question Does this mean marijuana is legal now, or that my doctor can prescribe it differently than before? The Bottom Line Not yet, and not automatically. Part of medical cannabis was reclassified in April 2026, the broader hearing on marijuana scheduling has closed without a decision, and this commentary argues the real clinical payoff still depends on research infrastructure states have not yet built. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview A hearing-adjacent policy commentary reads differently depending on whether you are the patient, the clinician, the researcher, or the skeptic in the room. These lenses keep the piece’s actual scope honest. #### Nothing Changes at Your Next Appointment Yet The DEA hearing on marijuana rescheduling has closed, but no final decision has been made, and the interim reclassification from April 2026 already covers state-licensed medical cannabis and FDA-approved products. You can still talk to your clinician honestly about cannabis use today; this commentary is about future research infrastructure, not a change to what is legal for you right now. Lens takeaway Keep discussing cannabis use with your clinician; this hearing closing does not change your legal status today. #### The Evidence Gap Will Not Close Automatically The commentary’s warning is directly relevant to daily practice: federal rescheduling lowering research barriers does not by itself produce the [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and real-world evidence clinicians need to counsel patients confidently. That means the evidence base clinicians rely on for many cannabis-related questions will likely stay thin in the near term, regardless of the hearing’s outcome, unless states actually fund the research infrastructure the authors describe. Lens takeaway Do not expect a wave of new clinical evidence simply because the hearing has closed. #### Lower Barriers Are Necessary but Not Sufficient Federal rescheduling can reduce some of the regulatory friction that has historically made cannabis research slow and expensive, but the commentary argues correctly that friction reduction alone does not create funding, infrastructure, or standardized data collection. The proposal for state-authorized, independent research centers with standardized metrics is aimed squarely at that gap, but it remains a proposal rather than a funded program as of this writing. Lens takeaway Track which states actually fund independent cannabis research infrastructure, not just which states have legal medical programs. #### The Hearing Closing Starts a Paper Process, Not a Verdict Post-hearing briefs are due August 17, 2026, after which the presiding judge will write a recommendation that the DEA Administrator can accept, reject, or modify on an unannounced timeline. That structure means the policy process has months of procedural steps left before any broader rescheduling outcome is final, even though the in-person hearing itself has concluded. Lens takeaway Expect a paper-based process through at least mid-fall 2026 before any recommendation is finalized. #### Litigation Is Still Running Alongside the Hearing Process Several lawsuits challenging the rescheduling move, filed by state attorneys general, rescheduling opponents, and at least one cannabis-focused biopharmaceutical company, have been consolidated in federal appellate court and remain unresolved. That litigation runs on a separate track from the DEA’s administrative hearing process, and either could affect the ultimate outcome independent of what the presiding judge recommends. Lens takeaway The administrative hearing closing does not resolve the parallel litigation over rescheduling. #### A Commentary Timed to News Is Still an Opinion Piece This is a three-author, peer-reviewed commentary published days after a major hearing closed, which makes it well-timed but does not make it empirical evidence or a neutral summary of the hearing record. Readers should treat its call for state-led research centers as an advocacy position grounded in real regulatory developments, not as a finding, prediction, or guarantee about what will happen next. Lens takeaway Well-timed commentary is still commentary, not data. #### Downstream Effects Are Already Uneven Across Agencies Agencies are not moving in lockstep. The ATF and Treasury Department have begun adjusting forms and guidance to reflect the April interim reclassification, while the Department of Transportation and Department of War have explicitly held their prior restrictions in place. Businesses and clinics operating across state lines should expect this patchwork of federal agency responses to continue regardless of how the broader hearing process concludes. Lens takeaway Do not assume every federal agency is treating cannabis the same way just because scheduling is changing. #### Watch the Briefs, the Recommendation, and State Funding Decisions The next concrete milestones are the August 17, 2026 post-hearing brief deadline, the presiding judge’s eventual recommendation, and the DEA Administrator’s final action on an unannounced timeline. Separately, and arguably more consequential for clinical evidence, is whether any state legislature actually funds the kind of independent research infrastructure this commentary proposes, which is worth tracking as its own story. Lens takeaway The hearing closing is a milestone to note, not the end of the story. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=The+DEA+Rescheduling+Hearing+Is+Over.+A+New+Commentary+Argues+States+Should+Lead+the+Next+Phase+of+Cannabis+Research&url=https%3A%2F%2Fcedclinic.com%2Fdea-rescheduling-hearing-state-led-cannabis-research-commentary%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fdea-rescheduling-hearing-state-led-cannabis-research-commentary%2F) [BlueSky](https://bsky.app/intent/compose?text=The+DEA+Rescheduling+Hearing+Is+Over.+A+New+Commentary+Argues+States+Should+Lead+the+Next+Phase+of+Cannabis+Research%20https%3A%2F%2Fcedclinic.com%2Fdea-rescheduling-hearing-state-led-cannabis-research-commentary%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Federal Rescheduling of Medical Cannabis: A Long-Overdue Opportunity to Lead with Science and Patient Care Realities.](https://pubmed.ncbi.nlm.nih.gov/42521587/) Related Reading at CED Clinic Continue exploring the evidence [Cannabis Was Just Removed From the Same Category as Heroin in the U.S.](https://cedclinic.com/cannabis-was-just-removed-from-the-same-category-as-heroin-in-the-u-s-the-historic/) CED coverage of the April 2026 interim reclassification of state-licensed medical cannabis and FDA-approved products to Schedule III, the reclassification this hearing builds on. [Read the rescheduling coverage](https://cedclinic.com/cannabis-was-just-removed-from-the-same-category-as-heroin-in-the-u-s-the-historic/) [Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products](https://cedclinic.com/dea-rescheduling-schedule-iii-cannabis-fda-approved-products/) Background on the federal scheduling framework referenced throughout this commentary, useful for readers who want the regulatory context in more depth. [Read the scheduling explainer](https://cedclinic.com/dea-rescheduling-schedule-iii-cannabis-fda-approved-products/) [Medical Cannabis: What to Tell Your Patients](https://cedclinic.com/medical-cannabis-what-to-tell-your-patients/) CED guidance for clinicians navigating cannabis conversations with patients while the evidence base and legal landscape continue to evolve. [Read the clinical counseling guide](https://cedclinic.com/medical-cannabis-what-to-tell-your-patients/) ## Frequently Asked Questions Did the DEA finish rescheduling marijuana in July 2026? No. The formal in-person hearing on the broader proposal to move marijuana to Schedule III closed in mid-July 2026, but the presiding judge has not issued a recommendation and the DEA Administrator has not made a final decision or set a timeline. What already changed before this hearing? In April 2026, the Acting Attorney General issued an order immediately reclassifying state-licensed medical cannabis and FDA-approved cannabis products from Schedule I to Schedule III. The hearing that just closed concerns a separate, broader rule. What happens next in the DEA hearing process? Participants may file post-hearing briefs of up to 50 pages by August 17, 2026. The presiding administrative law judge will use those briefs to write a recommendation, which the DEA Administrator can accept, reject, or modify. Who participated in the hearing? The DEA Administrator designated only parties opposed to rescheduling as official participants, including Smart Approaches to Marijuana, the National Drug & Alcohol Screening Association, the Tennessee Bureau of Investigation, DUID Victim Voices, and the states of Nebraska, Idaho, Indiana, and Louisiana. What does the new Clinical Therapeutics commentary argue? Authors Julie K. Johnson, Drudys Ledbetter, and Steph Sherer argue that federal rescheduling lowers barriers to cannabis research, but that states with mature medical cannabis programs must build independent, state-authorized research centers to convert that opening into usable clinical evidence. Is this commentary based on a new clinical trial? No. It is a peer-reviewed policy commentary, not a clinical trial or systematic review. It does not report new efficacy or safety data on cannabis. Has any state already built the research infrastructure the commentary describes? The commentary presents state-authorized, independent research centers as a proposal for what states should do next. It does not identify any state that has already fully built this model. Is litigation still affecting the rescheduling process? Yes. Several lawsuits challenging the rescheduling move, filed by state attorneys general, rescheduling opponents, and at least one cannabis-focused biopharmaceutical company, have been consolidated in federal appellate court and remain unresolved. Are all federal agencies treating cannabis the same way now? No. The ATF and Treasury Department have begun adjusting forms and guidance to reflect the April interim reclassification, while the Department of Transportation and Department of War have explicitly kept prior restrictions in place for safety-sensitive workers and military personnel. What is the most useful takeaway for a clinician reading this? The hearing closing is a procedural milestone, not a resolution, and the clinical evidence base for cannabis will likely improve only if states actually fund independent research infrastructure, not simply because federal scheduling changes. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).